Protein glycation refers to the reversible reaction between aldoses (or ketoses) and amino groups yielding relatively stable Amadori (or Heyns) products. Consecutive oxidative cleavage reactions of these products or the reaction of amino groups with other reactive substances (e.g. ␣-dicarbonyls) yield advanced glycation end products (AGEs) that can alter the structures and functions of proteins. AGEs have been identified in all organisms, and their contents appear to rise with some diseases, such as diabetes and obesity. Here, we report a pilot study using highly sensitive and specific proteomics approach to identify and quantify AGE modification sites in plasma proteins by reversed phase HPLC mass spectrometry in tryptic plasma digests. In total, 19 AGE modification sites corresponding to 11 proteins were identified in patients with type 2 diabetes mellitus under poor glycemic control. The modification degrees of 15 modification sites did not differ among cohorts of normoglycemic lean or obese and type 2 diabetes mellitus patients under good and poor glycemic control. The contents of two amide-AGEs in human serum albumin and apolipoprotein A-II were significantly higher in patients with poor glycemic control, although the plasma levels of both proteins were similar among all plasma samples. These two modification sites might be useful to predict long term, AGE-related complications in diabetic patients, such as impaired vision, increased arterial stiffness, or decreased kidney function.
The reaction between reducing sugars (i.e. aldoses or ketoses) and amines is termed glycation or nonenzymatic glycosylation (1) . The initially formed aldimines or ketimines can rearrange forming relatively stable Amadori or Heyns products, respectively. Consecutive rearrangements and oxidations yield advanced glycation end products (AGEs) 3 (2) (3) (4) (5) (6) , a structurally heterogeneous group of compounds including cross-linked proteins (1) . Alternatively, ␣-dicarbonyls generated by Ama-dori degradation (7, 8) , saccharide autoxidation (9, 10) , lipid peroxidation (11, 12) , and enzymatic reactions (13) (14) (15) can modify the side chains of lysine and arginine residues (16 -18) . Degradation of glucose-derived Amadori products, for example, yields 1-deoxyglucosone (7, 19) and its tautomers, which upon nucleophilic attack by a N ⑀ -amino group of a lysine residue undergo hydrolytic ␤-cleavage yielding amide-AGEs, such as N ⑀ -acetyl-, formyl-, and glycerinyl-lysine ( Fig. 1) (20) . Generally, AGEs can alter the structure of proteins contributing to diabetic retinopathy (21, 22) , increased arterial stiffness (23, 24) , or impaired renal function (25) along with aging and diabetes. Furthermore, receptor binding-induced activation of proinflammatory signaling pathways is associated with the development and progression of atherosclerosis (26) and nephropathy (25) .
AGEs have been localized in biological tissues by immunohistochemistry (27) (28) (29) and quantified with ELISA using monoclonal antibodies recognizing methylglyoxal-derived hydroimidazolone (30) , imidazolone (31) , pentosidine (32) , pyrraline (33) , and N ⑀ -carboxymethyl lysine (34, 35) . Alternatively, individual modifications were assayed by their intrinsic fluorescent properties (36 -38) or after derivatization with a fluorophore (37, 39) . AGEs can be detected likewise after chromatographic separation by mass spectrometry without derivatization in the multiple reaction monitoring mode, allowing their quantification with high sensitivity (40, 41) and robustness (42) . Characterization of amide-AGEs in proteomes will help with understanding the development of glycation-associated pathologies by identifying the affected protein (function) and providing access to subtissue level changes of individual residues prone to such modifications. We recently reported a two-step procedure to detect AGE-modified residues in plasma samples using specific and sensitive precursor ion scans (43, 44) . Here, we extended this approach by using gas phase fractionation to detect amide-bound AGEs that have been previously identified in lens homogenate (41) and as free adducts in human plasma and urine and found to be increased in uremic dialysis patients (45) . These peptides were relatively quantified in plasma samples obtained from obese type 2 diabetes mellitus (T2DM) patients with good or poor glycemic control and compared with healthy lean and obese persons.
Experimental Procedures
Materials-Chemicals and materials were from Carl Roth (Karlsruhe, Germany): tris(2-carboxyethyl)phosphine (Ն98%), glycerin (Ն99.5%); Biosolve (Valkenswaard, Netherlands): ace-tonitrile (Ն99.97%); AppliChem (Darmstadt, Germany): Tris (ultrapure); Serva Electrophoresis (Heidelberg, Germany): acrylamide/bis solution (37.5/1, 30% (w/v), 2.6% C), ammonium persulfate (analytical), N,N,NЈ,NЈ-tetramethylethylenediamine (research), Coomassie Brilliant Blue G-250 (pure), porcine trypsin (NB premium grade); Riedel-de-Haën (Seelze, Germany): bromophenole blue (reagent); Objective (Berlin, Germany): PicoTip online nano-ESI emitter (standard coating; outer diameter 360/20 m and tip internal diameter 10 m); Sartorius Stedim Biotech GmbH (Göttingen, Germany): Vivaspin filter devices (5000 molecular weight cut-off); Sigma-Aldrich: ammonium hydrogen carbonate, formic acid (ϳ98%), 2-mercaptoethanol (Ն99.0%). Water was purified in house (resistance Ն 18 m⍀, total organic content Ͻ 1 ppb) with a PureLab Ultra Analytic System (ELGA Lab Water, Celle, Germany).
Plasma Samples-Blood was obtained from male healthy, normoglycemic persons (HbA 1c Ͻ 5.6%; fasting plasma glucose Ͻ 6.0 mmol/liter) categorized as lean (body mass index Ͻ 25 kg/m 2 , n ϭ 6) or obese (body mass index Ͼ 30 kg/m 2 , n ϭ 5), as well as from obese T2DM patients (HbA 1c Ͼ 6.5%, fasting plasma glucose Ͼ 6.0 mmol/liter) being under poor (HbA 1c Ͼ 7.5%, n ϭ 5) or good glycemic control (HbA 1c ϭ 6 -7%, n ϭ 6). Cohorts were matched for age (50 years) and, in case of obese cohorts, for body mass index (supplemental Table S1 ). All blood samples were collected between 8 and 9 am after a 12-h fast in EDTA-treated tubes, blood cells were removed from plasma by centrifugation for 10 min at 2,000 ϫ g, and the separated plasma was stored at Ϫ80°C. The study was approved by the ethics committee of the University of Leipzig (approval no. 159-12-21052012), and all subjects gave written informed consent before taking part in the study.
Tryptic Digestion-Plasma samples (100 l) were depleted of lipids by centrifugation (9168 ϫ g, 30 min, 4°C), an aliquot (20 l) diluted 10-fold with ammonium hydrogen carbonate buffer (0.1 mol/liter, pH 8.0), and desalted using ultrafiltration (Vivaspin filter devices, 0.5 ml, 5-kDa cut-off). Protein concentrations were determined by a Bradford assay (46) . Briefly, acidic Coomassie Brilliant Blue G-250 solution (0.1 g/liter in 10% (v/v) H 3 PO 4 , 5% (v/v) aqueous ethanol, 250 l) was mixed with the protein sample (5 l) in a 96-well microtiter plate, and the absorption was recorded in two replicates at 595 nm. Quantification relied on a 2-fold dilution series of BSA (1000 to 62.5 g/liter). Plasma aliquots corresponding to a protein content of 25 g were complemented with SDS (10% (w/v) in water, 2 l) and tris(2-carboxyethyl)phosphine (50 mmol/liter in water, 2 l), diluted with aqueous ammonium hydrogen carbonate buffer (50 mmol/liter, pH 8.0) to obtain a final volume of 20 l, and incubated at 60°C for 15 min. The samples were cooled to room temperature, alkylated with iodoacetamide (0.1 mol/liter, 2.2 l) in the darkness (15 min, room temperature), and digested with trypsin (25 mg/liter in 50 mmol/liter ammonium hydrogen carbonate, 50 l, 37°C, overnight). The digest was frozen and stored at Ϫ80°C. An aliquot (2 g protein) of the sample was diluted with sample buffer (0.05% (w/v) bromphenol blue, 62.5 mmol/liter Tris-HCl, pH 6.8, 20% (v/v) glycerin, 2% (w/v) SDS, 5% (v/v) ␤-mercaptoethanol) at least 2-fold and heated to 95°C for 5 min. Proteins were separated by SDS-PAGE (T ϭ 12%, C ϭ 2.65%) (47) and stained with colloidal Coomassie Brilliant Blue G 250 (48) . The digestion step was considered complete (Ͼ 99%) when the original HSA band was not detected.
Nano UPLC-ESI-Linear Ion Trap-Orbitrap-MS-Plasma samples (75 ng) were loaded on a nanoAcquity UPLC Symmetry TM trap column using a flow rate of 5 l/min for 5 min and separated on a nanoAcquity UPLC BEH130 TM column (30°C) using a nanoAcquity TM UPLC System equipped with an Acquity sample manager (10 l of injection volume, full loop injection) and a nanoAcquity UPLC binary solvent manager (Waters, Eschborn, Germany). Eluents A and B were water and acetonitrile, respectively, both containing formic acid (0.1% v/v). The peptides were eluted with a linear, two-step gradient (3 3 50% eluent B in 45 min, 50 3 85% eluent B in 2 min) at a flow rate of 0.4 l/min. The column was connected via a PicoTip online nano-ESI emitter to a nanoESI-Orbitrap-MS (LTQ Orbitrap XL ETD) operated in positive ion mode and controlled by Xcalibur 2.0.7 software (Thermo Fisher Scientific, Bremen, Germany). Mass spectra were acquired in the Orbitrap at a resolution of 60,000. Tandem mass spectra (MS/MS) were recorded for the six most intense signals (z Ն 2) of an Orbitrap survey scan by data-dependent acquisition in the linear ion trap. Tandem mass spectra were analyzed with Sequest against the SwissProt database using Proteome Discoverer 1.1.0.263 (Thermo Fisher Scientific). Amide-AGE-modified peptides identified with an Xcorr below 2.20 for doubly and 3.75 for triply protonated ions were manually confirmed (49) . Relative, label-free quantification relied on the integration of extracted ion chromatograms (m/z Ϯ 0.02) for each of the three technical replicates acquired per sample (supplemental Table S2 ).
Statistics-Cohort comparison, statistical calculations, and graphical display were performed with the software GraphPad Prism 5.02 testing the technical replicates' averages within a cohort first for normal distribution (Kolmogorov-Smirnov test, ␣ ϭ 0.05). If both cohorts to be compared showed normal distribution, a t test was performed to assess the significance of differences. Otherwise, the nonparametric Mann-Whitney test was used (both two-sided, ␣ ϭ 0.05). Correlation analysis was performed using linear regression.
Results
Detection of Amide-AGEs in Diabetic Plasma-A pooled tryptic plasma digest obtained from five poorly controlled T2DM patients was analyzed repeatedly by nano-reversed phase-UPLC-ESI-linear ion trap-Orbitrap-MS in gas phase fractionation mode by splitting the m/z range from 400 to 1400 in 18 consecutive intervals. When the tandem mass spectra acquired in data-dependent acquisition mode were searched for amide-AGE-modified peptides, 2 glycerinylated, 7 acety- lated, and 10 formylated peptides were identified corresponding to 11 proteins (Table 1) within the 2626 peptides identified with high and medium confidence by Sequest. For example, peptide SK formyl EQLTPLIK (m/z 592.8457, z ϭ 2) corresponding to apolipoprotein A-II 68 -77 (processed: 50 -59) eluted at 25.6 min, whereas further isobaric peptides IQNILTEEPK (m/z 592.8289, z ϭ 2, serum paraoxonase/arylersterase 1) and DVE-DAHSGLLK (first 13 C-isotope of m/z 592.3051, z ϭ 2, N-acetylglucosamine-1-phosphotransferase subunits ␣/␤) eluted at 24.1 and 26.6 min, respectively (Fig. 2) .
Quantification of Amide-AGEs in Plasma-Seventeen of the identified amide-AGE-modified peptides could be quantified by the peak areas displayed in the extracted ion chromatograms in all plasma samples with relative standard deviations among the technical replicates typically below 60%, except for DRQC diox K acetyl YIW ox GQK, which was not detected in samples 17, 19, and 22. Peptides EFAK acetyl EIDISCVK and LK acetyl C ox DEW diox SVNSVGK were detected in all or only seven samples, respectively, but always too weak for quantification (signal to noise ratio Ͻ 10). The physiological state of the subjects (normoglycemic lean or obese, well or poorly controlled T2DM) did not affect the quantities of 15 of the 17 peptides (p Ͼ 0.05, average differences Ͻ 50%; supplemental Fig. S1 ). In contrast, LK acetyl C cam ASLQK (HSA 222-229, processed: 198 -205) allowed distinguishing poorly controlled diabetic patients from lean healthy persons (p ϭ 0.017, without highest data point: p ϭ 0.038; Fig. 3A ). Moreover, SK formyl -EQLTPLIK from apolipoprotein A-II ( Fig. 3B ) was able to discriminate poorly controlled patients with T2DM from all other cohorts (all p Ͻ 0.002). To ensure that these higher levels in poorly controlled patients with T2DM were not associated with an elevated level of the protein (i.e. similar modification rate, but higher protein quantities), nonmodified peptides corresponding to both proteins were quantified as well. HSA quantification relied on 21 non-AGE-modified peptides identified with high and one peptide (LKC cam ASLQK) with medium confidence scores (49) (all peptides ranked at position 1), whereas five peptides of medium confidence were chosen for apolipoprotein A-II (supplemental Table S3 ). Because the plasma levels of both proteins (assessed via the majority of the non-AGEmodified peptides; supplemental Fig. S2 ) did not differ between the groups, the increase in modified peptides can be attributed solely to elevated modification degrees at both sites. The modification rate of LKC cam ASLQK (HSA) was even so high that the quantity of the unmodified peptide decreased in the poorly controlled patients with T2DM relative to all other cohorts albeit not significantly (p Ͼ 0.05; supplemental Fig. S2G ). Most likely, the lower content of the unmodified peptide was not attributed completely to the acetyl-AGE, but to other AGE modifications as well. The obtained differences in the cohort averages among the background of a limited cohort size (n) and the observed intracohort standard deviations () were statistically evaluated for the minimum meaningful difference (d). The minimum n required to demonstrate meaningful d with typical confidence levels (␣ ϭ 0.05, ␤ ϭ 0.2) was calculated with the transposed form of formula n ϭ 16 ϫ 2 /d 2 . Indeed, the minimum d calculated for SK formyl EQLTPLIK between T2DM_LT and T2DM_MT was by a factor of 0.75 smaller than the observed differences of the cohort averages.
Correlation analysis with the patients' clinical data (supplemental Table S1) showed either none or only weak associations to body mass index, plasma protein concentration, or HbA 1c except for SK formyl EQLTPLIK (apolipoprotein A-II), which strongly correlated to HbA 1c (R 2 ϭ 0.79; Fig. 4 ).
Discussion
Detection of Amide-AGEs in Diabetic Plasma-The structures of peptides comprising N ⑀ -acetylated, formylated, and glycerinylated lysine residues can be easily determined by tandem mass spectrometry, because all three modifications are stable against collision-induced dissociation (50) . Thus, standard MS-based proteomic approaches can be applied to identify accordingly modified sites. Gas phase fractionation of pooled plasma samples was sufficiently sensitive to identify 19 modified sites in 11 plasma proteins. Most common were acetylation and formylation sites among the identified amide-AGEs, which is in accordance with the ratio of free AGE-modified amino acids in healthy and uremic plasma (45) . Other modification sources apart from nonenzymatic glycosylation might be enzymatic reactions or acetylating agents (e.g. acetylsalicylic acid). Lys 223 is the first site that was identified in HSA to be acetylated by acetylsalicylic acid (51) and was, together with Lys 549 , detected in "pure" HSA products (52) . Additionally, acetylated Lys 88 was detected in nondiabetic plasma even prior to incubation with acetylsalicylic acid (53) , but none of the other sites observed after HSA or plasma incubation with acetylsalicylic acid were found (52, 53) . Enzymatic acetylation (and formylation) are regulatory functions in nucleus, liver cell cytosols, and mitochondria (54) , but such activities have not been reported to our knowledge in plasma. In contrast, all HSA and apolipoprotein A-II sites identified here as modified by amide-AGEs are known to be glycated in plasma from patients with T2DM (55, 56) , indicating that these sites are susceptible to glycation finally leading to AGEs.
Relative Label-free Quantification of Amide-AGE Peptides in Plasma-Fifteen peptides (90%) were present in comparable quantities in all plasma samples indicating a relatively constant basic level of AGEs in human plasma that is not influenced by obesity and diabetes. This view is supported by studies at the amino acid level of plasma protein hydrolysates that detected similar global AGE levels in healthy persons (45, 57) .
Most detected AGE modification levels were not influenced by the patients' glycemic status considering the HbA 1c level. This is probably attributed to the different formation pathways of the N ␣ -(fructosyl) moiety, because hemoglobin is directly modified by glucose, whereas the studied N ⑀ -AGEs require first glucose degradation prior to alkylation of lysine residues. Further parameters probably contributing to the lower sensitivity in reflecting the blood glucose level are the different protein localizations (intracellular versus plasma), protein life times, and the site-specific susceptibilities to undergo modification. Thus, N ⑀ -AGEs are likely long term markers. Indeed, two amide-AGE modification sites were present at elevated levels in diabetic patients with poor glycemic control, most likely representing highly susceptible residues. Additionally, the generally poor correlation of the modification degrees among different sites within one protein (data not shown) emphasizes the sitespecific susceptibilities. This might be attributed to nearby residues or more generally the local environment, i.e. reagent accessibility and nearby functional groups affecting the pK a of the Lys residue or acting as local acid/base catalysts in glycation reactions (56, 58, 59) . Furthermore, the differences were relatively moderate (3-6-fold compared with the other cohorts) and were detected only in one peptide per modification type, which suggests that the changes would not be detectable with an analytical approach relying on protein hydrolysis. Hence, AGE modification sites appear to be highly relevant as biomarkers and to understand the pathology of diabetes. Compared with the glycemically poorly controlled patients with T2DM, the well controlled cohort showed SK formyl -EQLTPLIK levels comparable with healthy controls (Fig. 3B) , illustrating on the molecular level that glycemic control does not only reduce protein glycation levels but also prevents elevated advanced glycation degrees at sites prone to AGE modifications. Thereby, the T2DM-associated risk to develop AGErelated severe complications can be reduced, which has been previously supported by clinical studies (60) . The two amide-AGE modification sites identified here closely resemble poorly controlled patients with T2DM and thus might be helpful to monitor the risk of late complications in diabetes. However, the three individuals showing much higher LK acetyl C cam ASLQK levels compared with all other participants (patients 3, 8, and 14), underwent prescribed acetylsalicylic acid treatment, which most likely caused the modification increase and thus may impact its biomarker value.
In conclusion, we demonstrate that bottom-up MS-based proteomics is sufficiently sensitive to detect protein-bound amide-AGE modifications in human plasma without the need for AGE enrichment strategies, which simplifies the analysis and improves the robustness. Because of the site-specific response to the glycemic status in patients, which were most likely subtissue level changes, we conclude that site-specific detection and quantification of AGEs may prove very useful in AGE-related biomarker discovery and pathology research. However, validation of these results in larger cohorts and with more robust quantification methods (e.g. LC-multiple reaction monitoring) is required in future. Those studies could probably reveal whether and which AGE sites could be suitable as biomarkers reflecting the disease severity in a graded manner, which could be useful to trace or even predict disease progression toward severe complications. As further amide-AGE sites were detected, albeit at too low confidence, further fractionation via orthogonal separation techniques like hydrophilic interaction chromatography might extend the range of detectable modification sites even further.
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